When Capital Comes Back, Which Healthcare Companies Will Be Ready?

There are signs that the IPO market is coming back.

EY's latest Global IPO Trends report says momentum strengthened during the first half of 2026, with investor demand appearing across several sectors, including biotech. The UK is also showing early signs of recovery after a difficult period for new listings.

That is encouraging news for healthcare and life sciences companies that have spent the last several years waiting for capital markets to improve.

But an open IPO window does not necessarily mean a company is ready to walk through it.

For healthcare, there is another question executives should be asking: How well will our regulatory, reimbursement and policy assumptions hold up when public investors start looking closely at the business?

Capital is only part of the story

Earlier this year, I explored this issue in Episode 4 of The Ron Lanton Report: From Innovation to Infrastructure: What Gets Funded, What Gets Built.

The basic idea was that innovation alone does not determine what ultimately succeeds in healthcare. Capital flows toward companies that can turn an idea into something the healthcare system can actually support.

The improving IPO environment puts that question back on the table.

EY's analysis is particularly interesting because it describes an IPO market where capital is available, but the windows to access it can still be short. Companies therefore need to be ready before the opportunity appears.

For healthcare companies, readiness means more than audited financial statements and a compelling investor presentation.

It also means understanding the policy assumptions underneath the revenue story.

Investors will look beneath the growth forecast

Consider a biotech company preparing for the public markets.

Its valuation may depend on assumptions about FDA approval, reimbursement, launch timing and the prices its products can command in major markets.

Those assumptions are becoming more complicated.

Drug pricing is now intersecting with trade policy. MFN could change international pricing assumptions. The Inflation Reduction Act continues to influence product economics in the United States. European reimbursement decisions can affect global launch strategies.

A company can have excellent science and still face questions about whether its commercial assumptions will hold.

The same applies outside biopharma.

A digital health company may have strong adoption but still depend on reimbursement policies that could change.

A specialty pharmacy may be growing rapidly while facing PBM network pressure or limited distribution constraints.

A diagnostics company may have compelling technology but still need payer coverage before widespread adoption becomes possible.

Those are not simply regulatory issues.

They can become valuation issues.

Healthcare IPO readiness is becoming broader

This is where I think healthcare executives need to think differently about IPO readiness.

The traditional question is whether the company is financially and operationally prepared to become public.

That remains essential.

But healthcare companies should also be asking whether they can explain the external environment surrounding their business.

What happens if reimbursement changes?

How exposed is the business to one payer, government program or regulatory decision?

Could a policy development change the company's pricing assumptions?

Does international expansion introduce another layer of regulatory or geopolitical risk?

These are questions companies should understand before investors start asking them.

The window may not stay open forever

EY makes another point worth paying attention to: IPO windows can still be episodic.

Geopolitics, large offerings and changes in investor sentiment can quickly alter market conditions.

That means healthcare companies waiting for the perfect market may be thinking about the problem backwards.

The time to prepare for an IPO window is not when everyone agrees that the window has opened.

It is before that happens.

At Lanton Strategies International, this is one of the intersections we watch closely. Capital strategy in healthcare cannot be separated completely from reimbursement, regulation, trade and government policy because those forces ultimately influence the assumptions investors make about growth.

The capital markets may be getting healthier.

For healthcare companies thinking about an IPO, the more important question is whether the business is ready when investors come looking.

Because when the window opens, there may not be much time to get ready.

Independent analysis from Lanton Strategies International. This article does not constitute legal or investment advice.

Germany’s Drug Pricing Dispute Now Has a Comment Deadline. Stakeholders Should Pay Attention.

Germany’s pharmaceutical pricing and reimbursement system has moved into a new arena.

In June 2026, the Office of the United States Trade Representative launched a Section 301 investigation titled “Germany’s Persistent Underpayment for Innovative Pharmaceutical Products.” The investigation focuses on whether Germany’s pharmaceutical pricing and reimbursement practices may be unreasonable, discriminatory, or burdensome to U.S. commerce.

The USTR comment docket opened on June 25, 2026. Written comments are due by August 10, 2026, at 11:59 PM EDT.

For German companies, investors, trade associations, and policymakers, this should not be viewed as a routine U.S. trade development.

It is a signal that drug pricing is becoming part of international economic policy.

For many years, pharmaceutical pricing was treated primarily as a domestic healthcare issue. Germany had its system. The United Kingdom had its system. France, the Netherlands, Italy, Spain, and other countries had their own reimbursement frameworks.

Companies still had to understand each market on its own terms. Germany was different from the UK. France was different from the Netherlands. Pricing and reimbursement strategy had to account for those differences, but the debate usually stayed inside the healthcare policy framework.

That is starting to change.

The U.S. government is now using a trade law mechanism to scrutinize how another advanced economy pays for innovative medicines. That does not mean the United States will automatically prevail. It also does not mean Germany will suddenly redesign its statutory health insurance system around U.S. objections.

It does mean the policy risk has changed.

Germany matters because it is one of Europe’s most important pharmaceutical markets. Decisions made in Germany can affect launch sequencing, reference pricing, investor assumptions, and commercial planning across multiple markets.

The U.S. argument appears to be that American patients and the U.S. market are carrying too much of the global cost of pharmaceutical innovation while other wealthy countries use reimbursement systems to pay less.

German and European policymakers are likely to see the issue very differently. From their perspective, pharmaceutical reimbursement is part of national healthcare policy, public budgeting, and statutory insurance design.

That tension is exactly why this investigation matters.

For German life sciences companies and investors, the issue is not only whether this ends with tariffs, negotiations, or no immediate action.

The more important point is that pharmaceutical pricing is being pulled into a wider conversation about trade, investment, reimbursement, and market access.

That has practical consequences. A German pricing decision may no longer stay inside Germany. It can affect launch strategy, investor assumptions, reference pricing, and how policymakers in Washington view the balance between innovation, access, and cost.

The USTR comment period gives stakeholders an opportunity to shape the record. A strong submission should not simply defend or criticize German pricing policy. It should explain the commercial, legal, reimbursement, innovation, and patient-access consequences in a way that U.S. trade policymakers can understand.

At Lanton Strategies International, we help companies, investors, and associations understand how policy developments across the U.S., EU, and UK affect market strategy, pricing risk, reimbursement positioning, and capital planning.

For stakeholders considering whether to submit comments, we can help assess the USTR investigation, develop comment strategy, identify the business and policy issues that should be raised, and translate German reimbursement concerns into the language of U.S. trade policy.

The Germany Section 301 investigation is one of those moments where healthcare policy, trade policy, and commercial strategy are no longer separate conversations.

For German life sciences companies, investors, and associations, the time to assess the issue is now.

When Regulatory Signals Reshape Valuation

For decades, the expectation that most new drugs would be supported by two adequate and well-controlled clinical trials operated as a structural assumption in the US regulatory system. It wasn’t simply a procedural norm. It became embedded in how companies planned development timelines, how investors modeled risk, and how boards evaluated capital allocation. Even when flexibility existed in practice, the baseline expectation created predictability. Predictability supports valuation.

When longstanding evidentiary expectations begin to evolve, even in subtle ways, the implications extend far beyond regulatory interpretation. They move directly into capital strategy.

At first glance, reconsidering the traditional two-trial expectation sounds technical. It feels like something that belongs in a regulatory affairs update or a clinical development memo. But step back. If the evidentiary framework shifts, development timelines may compress. If timelines compress, capital burn assumptions change. If capital burn assumptions change, fundraising strategy changes. When fundraising strategy changes, valuation follows.

That is not compliance. That is capital architecture.

The two trial expectation functioned as a stabilizing reference point. Sponsors understood the evidentiary threshold. Investors priced in the development pathway. Analysts anchored risk models to a familiar structure. When that baseline assumption begins to move, even in the direction of greater flexibility, discretion expands. Expanded discretion introduces both opportunity and variability.

Acceleration can increase capital efficiency. Variability can increase perceived risk.

Markets react to both.

Flexibility does not mean deregulation. The FDA’s mandate to ensure safety and efficacy remains central. The way evidentiary standards are interpreted, along with the circumstances under which alternative evidence may be considered sufficient, directly influences capital confidence. Regulatory posture now enters financial forecasting earlier in the lifecycle. It no longer waits for final approval to shape valuation assumptions.

For early-stage biotech firms, this can alter milestone sequencing and investor communication strategy. For later-stage sponsors, it may influence launch timing, commercialization planning, and capital deployment decisions. For institutional investors, it introduces a recalibration moment: how durable are existing risk assumptions if the evidentiary baseline becomes more fluid?

This development also carries transatlantic implications. For European life sciences companies seeking US market entry, the FDA approval pathway often anchors global strategy. If US evidentiary flexibility increases, development sequencing between the FDA and EMA may shift. Capital raises tied to anticipated regulatory inflection points may need re-modeling. Investor appetite across jurisdictions may adjust in response to perceived regulatory momentum.

Regulatory posture in Washington increasingly shapes boardroom discussions in Amsterdam, Berlin, and London.

The larger point is not about one evidentiary standard. It is about what happens when foundational assumptions begin to move. Healthcare regulation has always shaped market behavior. What is different now is the speed with which policy signals enter valuation models. Investors respond to direction as much as finality. Executive teams adjust capital strategy in response to posture, not just published guidance.

When the baseline shifts, financial models must shift with it.

The reconsideration of longstanding evidentiary expectations illustrates a broader structural trend: policy is no longer confined to compliance architecture. It has become capital infrastructure.

Those who recognize that early are better positioned to scale.